|
US3992518A
(en)
|
1974-10-24 |
1976-11-16 |
G. D. Searle & Co. |
Method for making a microsealed delivery device
|
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
IE60901B1
(en)
|
1986-08-21 |
1994-08-24 |
Vestar Inc |
Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
US5660848A
(en)
|
1994-11-02 |
1997-08-26 |
The Population Council, Center For Biomedical Research |
Subdermally implantable device
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
ATE252372T1
(de)
|
1996-08-23 |
2003-11-15 |
Sequus Pharm Inc |
Liposome enthaltend cisplatin
|
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
WO1998016201A1
(en)
|
1996-10-11 |
1998-04-23 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method
|
|
AU2903999A
(en)
|
1998-03-12 |
1999-09-27 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
|
|
NZ514442A
(en)
|
1999-03-03 |
2003-08-29 |
Optinose As |
Nasal delivery device
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
CA2447632C
(en)
|
2000-06-16 |
2011-08-02 |
Asterion Limited |
Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
|
|
SI1724284T1
(sl)
|
2000-12-07 |
2009-12-31 |
Lilly Co Eli |
Glp-1 fuzijski proteini
|
|
HUP0400698A3
(en)
|
2001-02-06 |
2006-01-30 |
Merck Patent Gmbh |
Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
IL147412A0
(en)
|
2001-12-31 |
2002-08-14 |
Yeda Res & Dev |
The use of il6r/il6 chimera in nerve cell regeneration
|
|
SI1499729T1
(sl)
|
2002-04-18 |
2011-11-30 |
Yeda Res & Dev |
Derivati encima ki inducira nf-kappab njihova priprava in uporaba
|
|
AU2003228067B2
(en)
|
2002-04-22 |
2008-05-29 |
Recopharma Ab |
Mucin fusion polypeptide vaccines, compositions and methods of use thereof
|
|
AU2003264009A1
(en)
|
2002-08-15 |
2004-03-03 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
GB0315182D0
(en)
|
2003-06-28 |
2003-08-06 |
Asterion Ltd |
Cytokine variant polypeptides
|
|
CN100415765C
(zh)
|
2003-08-07 |
2008-09-03 |
宜康公司 |
兔单克隆抗体的人源化方法
|
|
WO2005034863A2
(en)
|
2003-10-03 |
2005-04-21 |
Jarikuma Corporation |
Countermeasures against malaria
|
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
US7576183B2
(en)
|
2003-12-24 |
2009-08-18 |
Los Alamos National Security, Llc |
Structure-based receptor MIMICS targeted against bacterial superantigen toxins
|
|
PL1765397T3
(pl)
|
2004-05-25 |
2013-04-30 |
Tactic Pharma Llc |
Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
|
|
CA2588449A1
(en)
|
2004-11-24 |
2006-06-01 |
Therakine Corporation |
An implant for intraocular drug delivery
|
|
US7829679B2
(en)
|
2005-08-12 |
2010-11-09 |
Riken |
Mucin-type glycoprotein and use thereof
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
JPWO2007063907A1
(ja)
|
2005-11-30 |
2009-05-07 |
塩野義製薬株式会社 |
ペプチド糖鎖付加体およびそれを有効成分とする医薬
|
|
ATE437889T1
(de)
|
2005-12-02 |
2009-08-15 |
Apceth Gmbh & Co Kg |
Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
|
|
TW200813091A
(en)
*
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
EP2114999A2
(en)
|
2006-12-12 |
2009-11-11 |
Biorexis Pharmaceutical Corporation |
Transferrin fusion protein libraries
|
|
US7816324B2
(en)
|
2007-03-13 |
2010-10-19 |
Board Of Regents, The University Of Texas System |
Composition and method for the treatment of diseases affected by a peptide receptor
|
|
EP2626372B1
(en)
|
2007-03-29 |
2018-03-21 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
JP2010526066A
(ja)
*
|
2007-04-23 |
2010-07-29 |
シェーリング コーポレイション |
抗mdl−1抗体
|
|
WO2008133928A2
(en)
|
2007-04-27 |
2008-11-06 |
The Gi Company, Inc. |
Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
|
|
NZ601583A
(en)
|
2007-05-21 |
2013-08-30 |
Bristol Myers Squibb Co |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
EP2173378B1
(en)
|
2007-06-27 |
2014-03-19 |
Admune Therapeutics LLC |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
EP2050759A1
(en)
|
2007-10-19 |
2009-04-22 |
CONARIS research institute AG |
Soluble gp 130 muteins with improved binding activity
|
|
EP2294208B1
(en)
|
2008-05-29 |
2013-05-08 |
The Board of Trustees of The Leland Stanford Junior University |
Cell line, system and method for optical control of secondary messengers
|
|
BRPI0914889A2
(pt)
|
2008-06-17 |
2015-11-24 |
Otsuka Chemical Co Ltd |
peptídeo glp-1 adicionado de cadeia oligossacarídica
|
|
GB0815216D0
(en)
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
JP2012525415A
(ja)
|
2009-05-01 |
2012-10-22 |
オプソテツク・コーポレイシヨン |
眼科疾患を処置または予防するための方法
|
|
WO2011100620A2
(en)
*
|
2010-02-12 |
2011-08-18 |
The Regents Of The University Of California |
Upar binding agents and methods of use thereof
|
|
US20130040845A1
(en)
|
2010-02-16 |
2013-02-14 |
Immune Disease Institute, Inc. |
Method for screening receptors/ligands interactions
|
|
EP2796467B1
(en)
|
2010-03-31 |
2018-03-28 |
Boehringer Ingelheim International GmbH |
Anti-CD40 antibodies
|
|
US8734774B2
(en)
|
2010-04-02 |
2014-05-27 |
University Of Rochester |
Protease activated cytokines
|
|
US9119869B2
(en)
|
2010-04-29 |
2015-09-01 |
Ronald J. Shebuski |
Mucin derived polypeptides
|
|
HRP20230776T1
(hr)
|
2010-07-29 |
2023-10-27 |
Buzzard Pharmaceuticals AB |
Himerni antagonisti receptora il-1 tipa i
|
|
JP6251570B2
(ja)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
多量体il−15可溶性融合分子並びにその製造及び使用方法
|
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
EA032681B1
(ru)
|
2012-11-27 |
2019-07-31 |
Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн |
ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
|
|
BR112016002753A2
(pt)
*
|
2013-08-13 |
2017-11-21 |
Sanofi Sa |
anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
|
|
WO2015124297A1
(en)
|
2014-02-19 |
2015-08-27 |
Merck Patent Gmbh |
Cancer-targeted il-12 immunotherapy
|
|
SG11201702295UA
(en)
*
|
2014-09-22 |
2017-04-27 |
Intrexon Corp |
Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
|
|
AU2016334401A1
(en)
*
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
|
JP7227007B2
(ja)
*
|
2015-12-02 |
2023-02-21 |
ストサイエンシス, インコーポレイテッド |
グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
|
|
US11104724B2
(en)
*
|
2016-05-23 |
2021-08-31 |
New York University |
Compositions and methods for antibodies targeting staphylococcal leukotoxins
|
|
EP3555127B1
(en)
*
|
2016-12-16 |
2024-12-18 |
H. Lundbeck A/S |
Agents, uses and methods
|
|
US10364286B2
(en)
*
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
|
US20200306301A1
(en)
*
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
CN110396133B
(zh)
*
|
2018-04-25 |
2021-07-23 |
免疫靶向有限公司 |
一种以白介素12为活性成分的融合蛋白型药物前体
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
WO2021074689A1
(en)
|
2019-10-18 |
2021-04-22 |
Alkermes Pharma Ireland Limited |
Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
|